1.	Organization

Juniper Pharmaceuticals, Inc. (the “Company” or “Juniper”), formerly known as Columbia Laboratories, Inc., was incorporated as a Delaware corporation in December 1986. The Company is a diversified healthcare company consisting of its Crinone® (progesterone gel) (“Crinone”) franchise and its fee-for-service pharmaceutical development and manufacturing business. Its marketed product and product development programs utilize its proprietary drug delivery technologies consisting of its bioadhesive delivery system (“BDS”), a polymer designed to adhere to epithelial surfaces or mucosa and its intra-vaginal ring (“IVR”) technology. In September 2013, the Company acquired Nottingham, U.K. based Juniper Pharma Services Ltd. (“Juniper Pharma Services”) formerly known as Molecular Profiles Ltd, a pharmaceutical services company. Juniper Pharma Services provides a range of drug development and consulting services to the pharmaceutical industry and has provided Juniper with an additional revenue source and in-house expertise for internal pharmaceutical programs.

At December 31, 2017, cash and cash equivalents were $21.4 million. The Company’s future funding requirements depend on a number of factors, including the rate of market acceptance of its current and future products and services and the resources the Company devotes to developing and supporting the same. The Company believes that current cash and cash equivalents, as well as cash generated from operations, will be sufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months from the date of the filing of this Form 10-K. The Company may be dependent on its ability raise additional capital to finance operations beyond March 2019 and fund research and development programs. If the Company is not able to raise additional capital on terms acceptable to it, or at all, as and when needed, it may be required to curtail its research and development programs.